NASDAQ · IOVA
Iovance Biotherapeutics, Inc.
$9.56-$5.25 (-35.45%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.8% below the high.
Loading market information…
NASDAQ · STTK · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Shattuck Labs, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Shattuck Labs, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Shattuck Labs, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 27, 2025 | -$0.37+2.63% vs estimate | $14.49M+1,712.86% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.33+19.51% vs estimate | $3.00M+1,098.8% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $16.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$9.56-$5.25 (-35.45%)
Iovance Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.8% below the high.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
$10.54-$0.08 (-0.75%)
Puma Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.35% below the high.
$14.07+$0.57 (+4.22%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$18.75-$0.45 (-2.34%)
Faeth Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.51% below the high.
$3.34+$0.01 (+0.3%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.96% below the high.
$1.21-$0.05 (-3.97%)
NovaBridge Biosciences’s quoted price sits in the lower half of its reported 52-week range, 76.69% below the high.
$1.86+$0.03 (+1.64%)
Black Diamond Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.35% below the high.
